Skip to content
2000
Volume 15, Issue 1
  • ISSN: 1573-4129
  • E-ISSN: 1875-676X

Abstract

Background: Capecitabine is an orally available prodrug of 5-flurouracil used in the treatment of breast cancer, metastatic colorectal cancer and stage III colorectal cancer. Various studies have reported the HPLC, HPLC-MS, MS/MS methods for estimation of capecitabine. However, till date HPTLC method for estimation of capecitabine and its validation is not reported in tablet dosage form. Introduction: Presented study deals with the development and validation of stability indicating high performance thin layer chromatography method for the determination of Capecitabine in tablet dosage form. Methods: The method was developed using precoated HPTLC plates with silica gel 60 F254 as stationary phase and toluene-methanol the ratio of 7.5:2.5 v/v as the mobile phase. Capecitabine (RF 0.48 ± 0.03) and its degradation products were well resolved. The wavelength selected for study was 240 nm. The method was linear in the concentration range 50–550 ng/band with a correlation coefficient of 0.994. The repeatability for six samples was 1.25% RSD. The intraday and interday precisions were 1.46-1.71%RSD and 1.31-1.67% RSD, respectively. The accuracy (recovery) was found to be in the range of 99.10-101.23% with LOD and LOQ were found to be 0.650 and 1.765 mg/band. The mean content of drug in tablet dosage form was found to be 101.51% with a % RSD of 1.20. The drug was subjected to stress conditions such as hydrolysis, oxidation, photolysis, and heat. Results: Degradation products produced as a result of the stress conditions did not interfere with the detection of Capecitabine; therefore, the proposed technique can be considered stability-indicating. Capecitabine did not degrade under thermal and photolytic conditions but showed degradation under acidic and alkaline conditions with 15 and 11% decompositions respectively. Conclusion: The developed method was found to be facile, simple, specific, precise, and stabilityindicating. It can be employed for the routine analysis of capecitabine in tablet dosage form.

Loading

Article metrics loading...

/content/journals/cpa/10.2174/1573412913666171023154934
2019-01-01
2025-09-02
Loading full text...

Full text loading...

/content/journals/cpa/10.2174/1573412913666171023154934
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test